2022 American Transplant Congress
Evaluation of Different Initial Tacrolimus Dosing Regimens in Pediatric Post-Liver Transplantation
*Purpose: Tacrolimus is an immunosuppressant used in post-liver transplantation, has wide pharmacokinetic variability, particularly in pediatric patients. Therefore, this study aimed to evaluate different weight-based…2022 American Transplant Congress
Long-Term Outcomes After Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant: A Matched Cohort Study
Paris Transplant Group, INSERM, Paris, France
*Purpose: Conversion to belatacept after transplant seems to be safe. However, no studies have reported the long-term efficacy and safety outcomes after conversion to belatacept…2022 American Transplant Congress
Predicted Performance of Bayesian-Based Precision Dosing Software for Tacrolimus
*Purpose: Bayesian-based precision dosing software (BPDS) has been utilized for therapeutic drug monitoring to optimize medication use. However, BPDS for tacrolimus (TAC) is not routinely…2022 American Transplant Congress
Conversion to Everolimus-Based Immunosuppression Regimen with Calcineurin Inhibitor Reduction Ameliorates Histological Damage in Kidney Transplant Recipients with Calcineurin Inhibitor-Induced Nephrotoxicity
Hokkaido University Hospital, Sapporo, Japan
*Purpose: In the last two decades, the short-term results for kidney transplantation (KTX) have improved owing to the use of calcineurin inhibitors (CNIs). However, long-term…2022 American Transplant Congress
Kidney Transplant Recipients Not Reaching the Expected Post-Transplant Creatinine Range Most Likely Show Calcineurin-Inhibitor Nephrotoxicity Upon Histology
1University Hospital Zürich, Zürich, Switzerland, 2University Hospital Zurich, Zürich, Switzerland
*Purpose: Very recently, our own data suggested that approximately 25% of deceased-donor kidney transplant recipients (KTRs) and 10% of living-donor KTRs don’t reach the expected…2022 American Transplant Congress
Impact of Early Calcineurin-Inhibitor Conversion to Belatacept on Renal Allograft Function in a Steroid-Free Maintenance Regimen: Results from a Randomized Controlled Study
*Purpose: Belatacept (Bela) was developed to minimize nephrotoxicity and cardiovascular risk associated with Calcineurin inhibitors (CNIs). Early steroid withdrawal (ESW) and simultaneous CNI avoidance (CNIA)…2021 American Transplant Congress
Quantifying the Interaction Between Posaconazole and Tacrolimus in Liver Transplant Recipients: A Practical Approach
*Purpose: The interaction between tacrolimus (FK) and posaconazole (POSA) is well documented, however the extent of this interaction and the practical management has yet to…2021 American Transplant Congress
Systematic Evaluation of Immunosuppressant Drug Tolerability in Lung Transplant Recipients with Short Telomere Syndrome
*Purpose: Lung transplant recipients with short telomere syndrome are at high risk of hematologic complications. Consequently, patients with short telomere syndrome may require more frequent…2021 American Transplant Congress
Unclear Implications of Tacrolimus Time in Therapeutic Range as a Predictor of Acute Rejection in Renal Transplant Recipients Undergoing Early Corticosteroid Withdrawal
University of Illinois at Chicago, Chicago, IL
*Purpose: Tacrolimus (TAC) demonstrates a wide intra- and inter-patient variability (IPV) necessitating therapeutic drug monitoring. The purpose of this study is to determine the impact…2021 American Transplant Congress
Cognition After Belatacept Conversion (CAB) Trial
1Yale University, New Haven, CT, 2Yale New Haven Hospital, New Haven, CT
*Purpose: Extensive adverse effect profiles including neurotoxicity, manifesting as short-term memory loss, make CNIs less desirable despite their efficacy preventing acute rejection and increasing graft…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 16
- Next Page »